肺癌与间皮瘤中的检查点阻断治疗
本文综述了免疫检查点抑制剂(CPI)在肺癌和间皮瘤中的标志性临床试验。在非小细胞肺癌中抗PD-1抗体已成为获批治疗手段,而在小细胞肺癌和间皮瘤中检查点抑制的疗效尚未被证实。多数试验应答率约20%,预测性生物标志物和联合治疗是提高疗效的关键方向。
要点
- 抗PD-1抗体已进入非小细胞肺癌的获批治疗 arsenal。
- 小细胞肺癌和间皮瘤中检查点抑制疗效尚未被证实。
- 多数临床试验应答率约20%,预测性生物标志物至关重要。
核心结论
- 检查点抑制剂在非小细胞肺癌中已成为获批治疗手段,但在小细胞肺癌和间皮瘤中疗效尚未证实。
- 多数临床试验应答率约20%,预测性生物标志物对充分发挥CPI潜力至关重要。
研究设计与样本
- 本文为简明临床综述,概述了肺癌和间皮瘤中检查点阻断的标志性临床试验。
主要发现
- PD-1-PD配体1/2通路和细胞毒性T淋巴细胞相关蛋白4是这些恶性肿瘤中研究最多的免疫治疗靶点。
- 在非小细胞肺癌中,抗PD-1抗体已成为获批治疗武器的一部分。
- 在小细胞肺癌和间皮瘤中,检查点抑制的疗效尚未被证实。
- 多数临床试验的应答率约为20%。
临床怎么用
- 在非小细胞肺癌中可考虑使用抗PD-1抗体作为获批治疗手段。
- 需关注预测性生物标志物以筛选可能从检查点抑制剂获益的患者。
局限性
- 多数临床试验应答率约20%,疗效仍有很大提升空间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the last decade, immunotherapy has emerged as a new treatment modality in cancer. The most success has been achieved with the class of checkpoint inhibitors (CPIs), antibodies that unleash the antitumor immune response. After the success in melanoma, numerous clinical trials are being conducted investigating CPIs in lung cancer and mesothelioma. The programmed death protein (PD) 1-PD ligand 1/2 pathway and cytotoxic T lymphocyte-associated protein 4 are currently the most studied immunotherapeutic targets in these malignancies. In non-small cell lung cancer, anti-PD-1 antibodies have become part of the approved treatment arsenal. In small cell lung cancer and mesothelioma, the efficacy of checkpoint inhibition has not yet been proven. In this Concise Clinical Review, an overview of the landmark clinical trials investigating checkpoint blockade in lung cancer and mesothelioma is provided. Because response rates are around 20% in the majority of clinical trials, there is much room for improvement. Predictive biomarkers are therefore essential to fully develop the potential of CPIs. To increase efficacy, multiple clinical trials investigating the combination of cytotoxic T lymphocyte-associated protein 4 inhibitors and PD-1/PD ligand 1 blockade in lung cancer and mesothelioma are being conducted. Given the potential benefit of immunotherapy, implementation of current and new knowledge in trial designs and interpretation of results is essential for moving forward.
引用
- Lievense LA, Sterman DH, Cornelissen R, et al. Checkpoint Blockade in Lung Cancer and Mesothelioma. Am J Respir Crit Care Med. 2017. PMID: 28252315. doi:10.1164/rccm.201608-1755CI
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。